NOX5 and p22phox are 2 novel regulators of human monocytic differentiation into dendritic cells

Blood. 2017 Oct 12;130(15):1734-1745. doi: 10.1182/blood-2016-10-746347. Epub 2017 Aug 22.

Abstract

Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells and are key cells of the immune system, acquiring different phenotypes in accordance with their localization during the immune response. A subset of inflammatory DCs is derived from circulating monocytes (Mo) and has a key role in inflammation and infection. The pathways controlling Mo-DC differentiation are not fully understood. Our objective was to investigate the possible role of nicotinamide adenine dinucleotide phosphate reduced form oxidases (NOXs) in Mo-DC differentiation. In this study, we revealed that Mo-DC differentiation was inhibited by NOX inhibitors and reactive oxygen species scavengers. We show that the Mo-DC differentiation was dependent on p22phox, and not on gp91phox/NOX2, as shown by the reduced Mo-DC differentiation observed in chronic granulomatous disease patients lacking p22phox. Moreover, we revealed that NOX5 expression was strongly increased during Mo-DC differentiation, but not during Mo-macrophage differentiation. NOX5 was expressed in circulating myeloid DC, and at a lower level in plasmacytoid DC. Interestingly, NOX5 was localized at the outer membrane of the mitochondria and interacted with p22phox in Mo-DC. Selective inhibitors and small interfering RNAs for NOX5 indicated that NOX5 controlled Mo-DC differentiation by regulating the JAK/STAT/MAPK and NFκB pathways. These data demonstrate that the NOX5-p22phox complex drives Mo-DC differentiation, and thus could be critical for immunity and inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation* / drug effects
  • Dendritic Cells / cytology*
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism
  • Enzyme Inhibitors / pharmacology
  • Free Radical Scavengers / pharmacology
  • Humans
  • Membrane Glycoproteins / metabolism
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / metabolism*
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondrial Membranes / drug effects
  • Mitochondrial Membranes / metabolism
  • Models, Biological
  • Monocytes / cytology*
  • Monocytes / drug effects
  • Monocytes / metabolism
  • NADPH Oxidase 2
  • NADPH Oxidase 5
  • NADPH Oxidases / antagonists & inhibitors
  • NADPH Oxidases / metabolism*
  • NF-kappa B / metabolism
  • Protein Binding / drug effects
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects

Substances

  • Enzyme Inhibitors
  • Free Radical Scavengers
  • Membrane Glycoproteins
  • Membrane Proteins
  • NF-kappa B
  • Reactive Oxygen Species
  • CYBB protein, human
  • NADPH Oxidase 2
  • NADPH Oxidase 5
  • NADPH Oxidases
  • NOX5 protein, human
  • CYBA protein, human